Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Current Deferred Revenue (2021 - 2025)

Core Scientific's Current Deferred Revenue history spans 5 years, with the latest figure at $150.1 million for Q2 2025.

  • For Q2 2025, Current Deferred Revenue rose 298.14% year-over-year to $150.1 million; the TTM value through Jun 2025 reached $150.1 million, up 298.14%, while the annual FY2024 figure was $18.1 million, 84.69% up from the prior year.
  • Current Deferred Revenue for Q2 2025 was $150.1 million at Core Scientific, up from $60.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $150.1 million in Q2 2025 and bottomed at $9.8 million in Q4 2023.
  • The 5-year median for Current Deferred Revenue is $62.2 million (2021), against an average of $70.5 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 87.39% in 2023 before it soared 298.14% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $63.4 million in 2021, then increased by 22.51% to $77.7 million in 2022, then tumbled by 87.39% to $9.8 million in 2023, then soared by 84.69% to $18.1 million in 2024, then surged by 729.28% to $150.1 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Current Deferred Revenue are $150.1 million (Q2 2025), $60.9 million (Q1 2025), and $18.1 million (Q4 2024).